It was hypothesized that C2 would benefit greatly from anti-PD-1 inhibitors based on the findings of the subgraph analyses between early-stage NSCLC patient samples and patients treated with NIVOLUMAB and PEMBROLIZUMAB (Figures 8(a) and 8(b)), which was consistent with the findings and hypotheses presented earlier. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.